HDM 2010
Alternative Names: HDM-2010Latest Information Update: 29 Jul 2024
At a glance
- Originator Hangzhou Zhongmei Huadong Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine phosphatase non-receptor type 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 31 May 2024 Preclinical trials in Solid tumours in China (unspecified route) prior to May 2024
- 31 May 2024 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical studies in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)